Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

© Shutterstock

Associate Professor Simon Rinaldi has received funding from the University of Oxford’s COVID-19 Research Response Fund to investigate this further. He and colleagues will compare the prevalence of SARS-CoV-2 polymerase chain reaction and seropositivity in a UK cohort of GBS patients identified during the pandemic, and compare GBS incidence rates to similar periods in previous years.

This will establish how often COVID-19 is complicated by GBS. By characterising COVID-GBS associated antibody and cytokine profiles, and evaluating their pathological effects in a myelinating culture model, the team will learn more about the underlying neuroimmunology of this disorder.